Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.
Anne Buot, Cecile Pallares, Alina Oganesyan, Charles Dauré, Valerie Bonnelle, Eric Burguière, Joao Flores Alves Dos Santos, Karim N’Diaye, Michael Ljuslin, Pauline Smith, Vincent Verroust, Benjamin Wyplosz, Margot Morgiève, Luc Mallet
Scientific Reports August 17, 2023 DOI: 10.1038/s41598-023-39812-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective online survey Peer reviewed |
|---|---|
| Sample size | 174 |
| Population | General population using psychoactive drugs |
| Keywords | Psychedelics Mental health OCD Treatment Therapeutic research Hallucinogens |
| Citations | 28 |
| Key findings | Classic psychedelics were the only substances reported as effective at reducing OCD symptoms, with symptom reduction associated with the intensity of acute effects. |
Abstract
A renewed interest in the use of psychedelics for treating obsessive compulsive disorder (OCD) has emerged in the last 20 years. But pre-clinical and clinical evidence remain scarce, and little is known about the factor determining the magnitude and persistence of the therapeutic effect. We therefore designed a retrospective online survey to explore, in the general population using psychoactive drugs, their impact on OCD symptoms. We also assessed the attitude of the participants towards the substance in term of frequency of intakes. In a sample of 174 participants, classic psychedelics were reported as the only substances effective at reducing OCD symptoms. In classic psychedelics users, symptoms reduction was associated with the intensity of acute effects, itself correlated to the dose. Reports on the persistence of the therapeutic effect varied from weeks to months, but we could not find any predicting factor. Finally, the occurrence and frequency of subsequent intakes, which seemed to be limited in our sample, were predicted by the magnitude and persistence of the therapeutic effect, respectively. Our observations support the hypothesis of classic psychedelics efficacy in reducing OCD symptoms but a careful evaluation of the persistence of this effect is still needed.
Citations in the library
Cited by 20
- Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms The International Journal of Neuropsychopharmacology November 29, 2024
- Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity. Neuropsychiatric Disease and Treatment 2025
- Existential feelings as a phenomenological framework for psychedelic therapy Philosophical Psychology October 9, 2024
- New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology? Pharmaceuticals April 30, 2025
- Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey. Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025
and 15 more in the library
Cites 34
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology November 8, 2017
- Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder The Journal of Clinical Psychiatry November 15, 2006
and 29 more in the library